Protein therapeutics offer high therapeutic potency and specificity; the broader adoptions and development of protein therapeutics, however, have been constricted by their intrinsic limitations such as inadequate stability, immunogenicity, suboptimal pharmacokinetics and biodistribution, and off-target effects. This review describes a platform technology that formulates individual protein molecules with a thin formulation layer of crosslinked polymers, which confers the protein therapeutics with high activity, enhanced stability, controlled release capability, reduced immunogenicity, improved pharmacokinetics and biodistribution, and ability to cross the blood brain barriers. Based on currently approved protein therapeutics, this formulating platform affords the development of a vast family of superior protein therapeutics with improved efficacy and broadened indications at significantly reduced cost.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571700PMC
http://dx.doi.org/10.1002/adma.202403116DOI Listing

Publication Analysis

Top Keywords

protein therapeutics
24
superior protein
8
efficacy broadened
8
pharmacokinetics biodistribution
8
protein
7
therapeutics
6
innovative formulation
4
formulation platform
4
platform paving
4
paving superior
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!